*Sponsored by GoldMining Inc.
Make sure set a reminder to join over 1000 traders in the Market Master’s trading room for live trading signals and education. We’re planning to stream Roaring Kitty at 12EST today so tune in!!!
FOCUS LIST🔎
GERN – Up over 38% in the pre market after receiving FDA approval of RYTELO™ (imetelstat) for treatment of adult patients with Lower-Risk MDS with Transfusion-Dependent Anemia
BCDA – Up over 45% in pre after announcing it has received a United States patent issuance on intramyocardial delivery of cell aggregates to the heart including minimally invasive radial artery approach
VERO – Up over 100% in pre after announcing it had regained NASDAQ compliance
*Sponsored by GoldMining Inc.
UPDATE: Since we first brought this company to your attention on Monday, it has made a nice 10%+ move higher over the week. Keep this stock on your watchlist and read the deep dive on our page HERE today 🤿.
In the late 1960’s, French President Charles De Gaulle set in motion the reduction of US economic influence by reducing French US dollar reserves by redeeming them for gold.
This set off other nations to do the same…and President Nixon was forced to close the “Gold Window”, which was the promise of the US Government to redeem US Dollars for gold.
In a decade, gold went on a bull run from $30 to $800, for a +2,500% price increase.
Fast forward to today’s playbook…China continues to purchase gold with US reserves (like the European nations in the 1970s).
And almost as powerful are the hundreds of millions of Chinese citizens also buying physical gold at unprecedented amounts.
This Historic Gold Rally Shows No Sign of the Chinese Stopping
The only question is: How could you try to take advantage of it?
We’re detailing one option to consider and research in this report.
We’ve found what might be a unique gold company that could benefit from gold’s historic rise in price.
CLICK HERE FOR OUR FULL REPORT
*Sponsored content/paid advertisement. This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results.
HOTLIST🔥
GERN – Up over 38% in the pre market after receiving FDA approval of RYTELO™ (imetelstat) for treatment of adult patients with Lower-Risk MDS with Transfusion-Dependent Anemia
Geron Corporation (GERN) is a late-stage clinical biopharmaceutical company that focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies.
Overnight, the company announced that it had received FDA approval of RYTELO™ (imetelstat) for treatment of adult patients with Lower-Risk MDS with Transfusion-Dependent Anemia.
Lower-risk MDS is a progressive blood cancer with high unmet need, where many patients with anemia become dependent on red blood cell transfusions, which can be associated with clinical consequences and decreased quality of life.
“With the approval and availability of RYTELO, we believe eligible patients with lower-risk MDS can potentially experience meaningful clinical benefit, particularly the potential for greater than 24 weeks of freedom from the burden of red blood cell transfusions and symptomatic anemia,” said John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer.
The stock traded up over 38% in the pre-market in reaction to the news.
The $5 area has acted as resistance in the pre-market and will be an important level to watch.
Above it, targets to the upside are $5.20, $5.30, $5.56 and then the pre-market high at $6.14. Beyond that, $6.50, $7 and $7.50 come into play.
Below $5, targets to the downside are $4.50, $4 and then a gap fill at $3.89.
BCDA – Up over 45% in pre after announcing it has received a United States patent issuance on intramyocardial delivery of cell aggregates to the heart including minimally invasive radial artery approach
BioCardia Inc. (BCDA) is a clinical-stage regenerative medicine company that develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States.
In the pre-market this morning the company announced it had received a United States patent issuance on intramyocardial delivery of cell aggregates to the heart including minimally invasive radial artery approach.
The Unites States Patent Office has granted Patent No: 11,986,611 titled “Radial and Transendocardial Delivery Catheter,” with a patent term that will expire in 2036.
The present invention relates to medical methods and systems suitable for substance delivery to the heart via a radial artery and for the intracardiac delivery of cellular aggregates and other agglomerated materials.
The stock traded up over 45% in the pre-market in reaction to the announcement.
$5.95 acted as support in the pre-market and will be an important level to watch.
Above it, targets to the upside are $6.70, $7 and then the pre-market high at $7.41. Beyond that, $8, $8.85 and $10 come into play.
Below $5.95, targets to the downside are $5.67, $5.20, $4.60 and then a gap fill at $4.37.
25 SEATS REMAIN!
VERO – Up over 100% in pre after announcing it had regained NASDAQ compliance
Venus Concept Inc. (VERO) is a medical technology company that develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally.
In the after-hours yesterday, the company announced that it had regained NASDAQ compliance.
The Nasdaq Staff originally issued the Company a deficiency notice on May 31, 2023, citing that stockholders’ equity as reported in the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2023, was below the minimum $2,500,000 required for continued listing.
On May 28, 2024, the Company completed a $35 million debt-to-equity transaction. As confirmed by the Nasdaq’s notice dated June 4, 2024, this transaction served to bring the Company into compliance with the Minimum Equity Requirement.
The stock traded up over 100% in the pre-market in reaction to the news.
The $1.20 area acted as support in the after-hours and pre-market and will be an important level to watch.
Above it, targets to the upside are $1.40, $1.60, $1.80, $2 and then the pre-market high at $2.15.
Below $1.20, targets to the downside are $1, $0.80 and then a gap fill at $0.5867.
MARKET NEWS 📰
👊 Make sure you are getting my mobile text alerts – text “RAGE” to 1-(888) 404-5747 to get all of my latest HOT STOCK ideas delivered right to your phone (make sure you put the “1” at the front!). Don’t miss out!
Questions or concerns about our products? Email Support@360wallstreet.io © Copyright 2022, RagingBull
*Just so you know, what you’re reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let’s be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren’t what you’d call “typical.”
Just a quick heads up about this ad you’re reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received thirty thousand dollars (cash) directly from GoldMining Inc
for a five day advertising marketing program starting on June 3, 2024 to help them reach a larger audience of prospective investors. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case.
Now, diving right into GoldMining Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there’s exceptional risk involved in trading. This isn’t small potatoes we’re talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We’re shining a light on the good stuff about the company here, but it’s on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.
Oh, that brings us to another crucial point—we’re not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.
Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can’t wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who’s licensed to give you real advice. To be clear,
Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1ties br0ker-dealer, br0ker, 1nvestment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry authority, or any self-regulat0ry organization.
So, that’s the scoop! If you’re intrigued and want to learn more about the companies we talk about, hit up the SEC’s website to dig into their filings and see the full picture.
